News | Contrast Media | November 29, 2015

Guerbet Completes Acquisition of Mallinckrodt’s Contrast Media and Delivery Systems Business

Guerbet board of directors approves 100 percent acquisition of Mallinckrodt division for $270 million

November 29, 2015 — Guerbet announced that it has completed its acquisition of the "contrast media and delivery systems" (CMDS) business of Mallinckrodt. The new entity brings together 2,500 employees, with a pro forma turnover of about €800M.

Guerbet’s board of directors approved the acquisition of the CMDS activity of Mallinckrodt on November 18.

The transaction has all necessary regulatory approvals and the customary closing conditions have been met.

Guerbet is acquiring 100 percent of the Mallinckrodt CMDS business for $270M total, paid in cash and financed by a loan syndicated by BNP Paribas. The acquisition relates to companies with their production sites, intellectual property rights and distribution subsidiaries in the various geographical areas. 

The complementary strengths of Guerbet and CMDS promise to bring rapid benefits, according to both companies: 

The strengths of Guerbet and CMDS will complement each other in several areas, according to the companies:

  • In contrast agents, where CMDS features Optiray and Optiject (Europe) / Ultraject (USA) in X-rays, and Guerbet offers Dotarem in magnetic resonance imaging (MRI);
     
  • In Imaging Solutions and Services, with CMDS’ syringe-based delivery systems and Guerbet’s  hydraulic injection technique for soft bags; and
     
  • From a geographical perspective, a similar synergy exists with a strong position of CMDS in the United States and Guerbet in Europe. In addition, Guerbet will strengthen its presence on markets with high growth potential, particularly in China, Russia, and Turkey.

In the medium-term, the group will achieve significant economies of scale, particularly by using the existing infrastructure and commercial networks to sell new products:

  • By pooling R&D and marketing resources;
  • By optimizing the purchasing, logistics and general spending policies of the two entities.

For more information: www.guerbet.com

Related Content

Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
ACR Introduces New Contrast Reaction Card
News | Contrast Media | February 07, 2018
The American College of Radiology (ACR) introduced a new contrast reaction card that summarizes important steps to be...
Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Overlay Init